KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBT Margin: 2017-2025

Historic EBT Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -120.61%.

  • Aquestive Therapeutics' EBT Margin fell 3562.00% to -120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.42%, marking a year-over-year increase of 58400.00%. This contributed to the annual value of -4,380.06% for FY2024, which is 436499.00% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported EBT Margin of -120.61% as of Q3 2025, which was up 10.95% from -135.44% recorded in Q2 2025.
  • Aquestive Therapeutics' EBT Margin's 5-year high stood at 72.46% during Q1 2023, with a 5-year trough of -618.35% in Q2 2021.
  • In the last 3 years, Aquestive Therapeutics' EBT Margin had a median value of -60.65% in 2023 and averaged -66.58%.
  • As far as peak fluctuations go, Aquestive Therapeutics' EBT Margin surged by 41,458bps in 2022, and later plummeted by 17,889bps in 2024.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' EBT Margin stood at -261.28% in 2021, then soared by 14,565bps to -115.63% in 2022, then spiked by 5,498bps to -60.65% in 2023, then spiked by 9,885bps to 38.20% in 2024, then tumbled by 3,562bps to -120.61% in 2025.
  • Its EBT Margin stands at -120.61% for Q3 2025, versus -135.44% for Q2 2025 and -262.96% for Q1 2025.